Key Points
- Omeros VP Peter Cancelmo sold 25,000 shares at an average price of $18.54, generating $463,500. Following the sale, he retained just 200 shares, representing a 99.21% reduction in his holdings.
- Omeros shares opened at $18.75, near their 12-month high of $19.65. The company reported quarterly EPS of $0.02, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded expectations.
- Institutional ownership stands at 48.79%, with major investors including BlackRock, Vanguard and UBS increasing or establishing positions. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $38.00.
Omeros Corporation (NASDAQ:OMER - Get Free Report) VP Peter Cancelmo sold 25,000 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president owned 200 shares of the company's stock, valued at $3,708. The trade was a 99.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Omeros Stock Down 0.2%
Shares of OMER stock opened at $18.75 on Wednesday. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $19.65. The stock's fifty day simple moving average is $12.98 and its 200 day simple moving average is $12.14. The firm has a market capitalization of $1.36 billion, a P/E ratio of 14.65 and a beta of 2.60.
Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.
Institutional Investors Weigh In On Omeros
Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Omeros in the second quarter valued at $57,484,000. Vanguard Group Inc. raised its position in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company's stock worth $68,929,000 after acquiring an additional 666,357 shares in the last quarter. UBS Group AG boosted its position in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock valued at $38,180,000 after purchasing an additional 1,513,893 shares in the last quarter. Geode Capital Management LLC grew its stake in Omeros by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company's stock worth $28,026,000 after purchasing an additional 95,979 shares during the period. Finally, State Street Corp increased its holdings in Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company's stock worth $27,025,000 after purchasing an additional 333,798 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
OMER has been the subject of several analyst reports. Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Zacks Research lowered Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a report on Monday, July 27th. Finally, Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $38.00.
View Our Latest Stock Report on OMER
About Omeros
(
Get Free Report)
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
